●  Founders

●  Scientific Advisory Board

●  Management

●  Investors

Constellation Pharmaceuticals’ Scientific Advisory Board: A powerful set of industry leaders who have the critical insights across all facets of biomedical and oncology and expertise in basic science, disease biology, chemistry, development and medicine.


Julian Adams, Ph.D.
Chief Scientific Officer, Infinity Pharmaceuticals

Stephen Baylin, M.D.
Deputy Director, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Xiaodong Cheng, Ph.D.
Professor, Emory University

Arul Chinnaiyan, M.D., Ph.D.
Professor of Pathology and Urology, University of Michigan

Steven Gamblin, Ph.D.
Professor, National Institute for Medical Research at the Medical Research Council, UK

Thomas Jenuwein, Ph.D.
Director, Max Planck Institute

Rick Klausner, M.D.
Managing Partner, The Column Group
and former Director of the National Cancer Institute

Arnold Levine, Ph.D.
Professor, Institute for Advanced Studies

David Livingston, M.D.
Deputy Director, Dana Farber Harvard Cancer Center

Scott Lowe, Ph.D.
Professor, Cold Spring Harbor Laboratory